Oncolys Biopharma, Inc. (4588) Press Release
Non-consolidated Financial Results for the Six Months Ended June 30, 2026 [Japanese GAAP]
Earlier from Oncolys Biopharma
- Oncolys BioPharma Announces Full Marketing Approval in Japan for Telomelysin for the Treatment of Esophageal Cancer
- Oncolys BioPharma: Non-consolidated Financial Results for the Three Months Ended March 31, 2026
- Oncolys BioPharma: Non-consolidated Financial Results for the Fiscal Year Ended December 31, 2025
- Oncolys BioPharma: Non-consolidated Financial Results for the Nine Months Ended September 30, 2025